The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
|Videos|December 6, 2018
Management of a Patient With a Very Large Ocular CSCC Tumor
Management of a Patient With a Very Large Ocular CSCC Tumor
Advertisement
A 64-Year-Old Woman With Very Large Ocular CSCC Tumor
- History
- A 64-year-old woman was referred for a left lower eyelid lesion that was rapidly increasing in size. She complained of intermittent twitching and numbness in the area. She reported that the lesion started on the lower eyelid.
- PMH: stent placed 10 years ago; hyperlipidemia, well controlled on simvastatin; hypertension, well controlled on metoprolol; rheumatoid arthritis
- PE
- Ulcerated lesion, approximately 8-mm in diameter
- ECOG PS 1
- Imaging confirmed perineural, vascular, and bone invasion
- Biopsy confirmed cutaneous squamous cell carcinoma, poorly-differentiated, Clark level V, perineural invasion, vascular invasion
- Stage: T3N0M0
Advertisement
Related to this article
Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
Late 2026 FDA oncology rulings may reshape care—from CSF-1R and ALK drugs to oral SERDs and BCMA CAR T breakthroughs.
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
September brought accelerated approvals in ESR1-mutant breast cancer and HER2-mutant non–small cell lung cancer, a Galleri panel vote, and a withdrawn I-DXd application.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
Denosumab Biosimilar Approved For Existing Oncology Indications
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5